Endorectal balloon enabled 78 Gy salvage boost for prostate-bed recurrence
In one macroscopic recurrence abutting rectum, an endorectal balloon reduced rectal V75 from 24.6% to 8.6%, enabling a 78 Gy boost.
In one macroscopic recurrence abutting rectum, an endorectal balloon reduced rectal V75 from 24.6% to 8.6%, enabling a 78 Gy boost.
TIMELESS scaffolded SIRT1-mediated Ku70 deacetylation, enhanced NHEJ repair and increased radioresistance in cervical cancer cells and xenografts.
In eight previously irradiated patients, CIRT achieved 71% one-year local control and 75% survival, with grade ≥3 toxicity in 25%.
ATG7 inhibition plus radiation doubled median survival versus untreated mice and produced long-term tumor-free survival in 40%.
Among 34 postoperative oral cavity cases, local failures occurred at or near the flap-native interface, with no recurrence inside the flap.
After surgery plus 66–70 Gy, only one of six patients recurred locally, while half developed distant metastases.
PACTUS 40 Gy/10 produced 30-month median survival in 28 selected frail patients, but incomplete response and toxicity data limit efficacy conclusions.
Wound dehiscence occurred in 78% of extensively involved keloid sites versus 5% of simple lesions after surgery and postoperative RT.
Short-course EBRT plus endorectal HDR brachytherapy produced 80% cCR/ncCR, but grade 3 late rectal toxicity occurred in 27%.
Concurrent durvalumab with either 60 Gy/15 or 60 Gy/30 was feasible in a 24-patient phase I study without concurrent chemotherapy.
In one cadaveric RCC plan, stable 1-cm perirenal separation reduced large-bowel Dmax from 34.5 to 22.1 Gy.
Seven patients completed 60 Gy with no recurrences, grade ≥3 skin toxicity, fibrosis, cartilage necrosis, or nasal contour deformation at early follow-up.
Four patients completed 54 Gy after airway reconstruction without graft-related toxicity or local recurrence during early follow-up.
A child developed hemorrhagic colitis after only 12.6 Gy(RBE), suggesting preceding intensive systemic therapy may increase bowel vulnerability.
All 50 proton SBRT fractions were completed, with online adaptation used in 84% to restore target coverage or resolve OAR violations.